Moderna target nearly halved by Morgan Stanley on weak guidance
Morgan Stanley slashed its price target on Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) to $38 from $70 given the lowered revenue guidance and ongoing competitive pressures in the vaccine market.
Is Moderna a Bad-News Buy for 2025?
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
No Evidence Woman's Breasts Grew to Triple G-Cup After Receiving COVID-19 Vaccine
No scientific studies have established a causal relationship between the Pfizer vaccine and conditions that cause the excessive growth of breasts.
The future of vaccines is needle-free
Beyond sidestepping people’s fear of needles, these vaccines would also make it easier to store and distribute ahead of ...
Amsterdam News14h
Factcheck: True: mRNA COVID-19 vaccines are safe and effective
BioNTech and Moderna COVID-19 vaccines use mRNA technology in their vaccines to protect us from the spread of the disease.
Moderna’s Financial Outlook: Hold Rating Amidst Competitive Challenges and Strategic Adjustments
In a report released today, Terence Flynn from Morgan Stanley assigned a Hold rating on Moderna (MRNA – Research Report), with a price target ...
Is Moderna Stock a No-Brainer Buy on the Sell-Off?
The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.
Vermont Business Magazine1d
VDH: COVID cases climb, along with deaths and hospitalizations
The VDH and Scott are advocating for people to get their vaccinations before winter. Scott said he has received his COVID ...
Five years after Covid, we scorn health workers, ignore vaccines and work in our offices
What happened to the need to end commuting and presenteeism? Or to our gratitude for healthcare workers or our resolution to ...